146 related articles for article (PubMed ID: 17266570)
1. Development of low molecular weight CXCR4 antagonists by exploratory structural tuning of cyclic tetra- and pentapeptide-scaffolds towards the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Tsutsumi H; Masuno H; Fujii N
Curr Med Chem; 2007; 14(1):93-102. PubMed ID: 17266570
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic potential of the chemokine receptor CXCR4 antagonists as multifunctional agents.
Tsutsumi H; Tanaka T; Ohashi N; Masuno H; Tamamura H; Hiramatsu K; Araki T; Ueda S; Oishi S; Fujii N
Biopolymers; 2007; 88(2):279-89. PubMed ID: 17167792
[TBL] [Abstract][Full Text] [Related]
3. The therapeutic potential of CXCR4 antagonists in the treatment of HIV infection, cancer metastasis and rheumatoid arthritis.
Tamamura H; Fujii N
Expert Opin Ther Targets; 2005 Dec; 9(6):1267-82. PubMed ID: 16300475
[TBL] [Abstract][Full Text] [Related]
4. Identification of a CXCR4 antagonist, a T140 analog, as an anti-rheumatoid arthritis agent.
Tamamura H; Fujisawa M; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2004 Jul; 569(1-3):99-104. PubMed ID: 15225616
[TBL] [Abstract][Full Text] [Related]
5. Development of a linear type of low molecular weight CXCR4 antagonists based on T140 analogs.
Tamamura H; Tsutsumi H; Masuno H; Mizokami S; Hiramatsu K; Wang Z; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Fujii N
Org Biomol Chem; 2006 Jun; 4(12):2354-7. PubMed ID: 16763678
[TBL] [Abstract][Full Text] [Related]
6. Development of anti-HIV agents targeting dynamic supramolecular mechanism: entry and fusion inhibitors based on CXCR4/CCR5 antagonists and gp41-C34-remodeling peptides.
Tamamura H; Otaka A; Fujii N
Curr HIV Res; 2005 Oct; 3(4):289-301. PubMed ID: 16250877
[TBL] [Abstract][Full Text] [Related]
7. Exploratory studies on development of the chemokine receptor CXCR4 antagonists toward downsizing.
Tamamura H; Tsutsumi H; Nomura W; Fujii N
Perspect Medicin Chem; 2008 Feb; 2():1-9. PubMed ID: 19787093
[TBL] [Abstract][Full Text] [Related]
8. T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer.
Tamamura H; Hori A; Kanzaki N; Hiramatsu K; Mizumoto M; Nakashima H; Yamamoto N; Otaka A; Fujii N
FEBS Lett; 2003 Aug; 550(1-3):79-83. PubMed ID: 12935890
[TBL] [Abstract][Full Text] [Related]
9. The chemokine receptor CXCR4 as a therapeutic target for several diseases.
Tamamura H; Tsutsumi H; Fujii N
Mini Rev Med Chem; 2006 Sep; 6(9):989-95. PubMed ID: 17017998
[TBL] [Abstract][Full Text] [Related]
10. Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.
Yoshikawa Y; Kobayashi K; Oishi S; Fujii N; Furuya T
Bioorg Med Chem Lett; 2012 Mar; 22(6):2146-50. PubMed ID: 22365757
[TBL] [Abstract][Full Text] [Related]
11. Role of CXCR4 in HIV infection and its potential as a therapeutic target.
Murakami T; Yamamoto N
Future Microbiol; 2010 Jul; 5(7):1025-39. PubMed ID: 20632803
[TBL] [Abstract][Full Text] [Related]
12. A low-molecular-weight inhibitor against the chemokine receptor CXCR4: a strong anti-HIV peptide T140.
Tamamura H; Xu Y; Hattori T; Zhang X; Arakaki R; Kanbara K; Omagari A; Otaka A; Ibuka T; Yamamoto N; Nakashima H; Fujii N
Biochem Biophys Res Commun; 1998 Dec; 253(3):877-82. PubMed ID: 9918823
[TBL] [Abstract][Full Text] [Related]
13. Bivalent 14-mer peptide ligands of CXCR4 with polyproline linkers with anti-chemotactic activity against Jurkat cells.
Tanaka T; Aoki T; Nomura W; Tamamura H
J Pept Sci; 2017 Jul; 23(7-8):574-580. PubMed ID: 28078743
[TBL] [Abstract][Full Text] [Related]
14. Two orthogonal approaches to overcome multi-drug resistant HIV-1s: development of protease inhibitors and entry inhibitors based on CXCR4 antagonists.
Tamamura H; Fujii N
Curr Drug Targets Infect Disord; 2004 Jun; 4(2):103-10. PubMed ID: 15180458
[TBL] [Abstract][Full Text] [Related]
15. Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.
Tamamura H; Araki T; Ueda S; Wang Z; Oishi S; Esaka A; Trent JO; Nakashima H; Yamamoto N; Peiper SC; Otaka A; Fujii N
J Med Chem; 2005 May; 48(9):3280-9. PubMed ID: 15857134
[TBL] [Abstract][Full Text] [Related]
16. The CXCL12/CXCR4 axis as a therapeutic target in cancer and HIV-1 infection.
Patrussi L; Baldari CT
Curr Med Chem; 2011; 18(4):497-512. PubMed ID: 21143114
[TBL] [Abstract][Full Text] [Related]
17. Paradoxical downregulation of CXC chemokine receptor 4 induced by polyphemusin II-derived antagonists.
Masuda R; Oishi S; Tanahara N; Ohno H; Hirasawa A; Tsujimoto G; Yano Y; Matsuzaki K; Navenot JM; Peiper SC; Fujii N
Bioconjug Chem; 2012 Jun; 23(6):1259-65. PubMed ID: 22486464
[TBL] [Abstract][Full Text] [Related]
18. A minimalistic 3D pharmacophore model for cyclopentapeptide CXCR4 antagonists.
Våbenø J; Nikiforovich GV; Marshall GR
Biopolymers; 2006; 84(5):459-71. PubMed ID: 16552740
[TBL] [Abstract][Full Text] [Related]
19. Low-molecular-weight CXCR4 ligands with variable spacers.
Narumi T; Aikawa H; Tanaka T; Hashimoto C; Ohashi N; Nomura W; Kobayakawa T; Takano H; Hirota Y; Murakami T; Yamamoto N; Tamamura H
ChemMedChem; 2013 Jan; 8(1):118-24. PubMed ID: 23086703
[TBL] [Abstract][Full Text] [Related]
20. Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis.
Choi WT; Yang Y; Xu Y; An J
Curr Top Med Chem; 2014; 14(13):1574-89. PubMed ID: 25159167
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
